1
Takase Yasutaka, Watanabe Nobuhisa, Matsui Makoto, Ikuta Hironori, Kimura Teiji, Saeki Takao, Adachi Hideyuki, Tokumura Tadakazu, Mochida Hisatoshi, Akita Yasunori, Souda Shigeru: Nitrogenous heterocyclic compound.. Eisai, July 27, 1994: EP0607439-A1 (120 worldwide citation)

A nitrogenous heterocyclic compound represented by general formula (I) or a pharmacologically acceptable salt thereof, efficacious in treating various ischemic cardiac diseases, wherein ring A represents a benzene, pyridine or cyclohexane ring; ring B represents a pyridine, pyrimidine or imidazole r ...


2
Souda Shigeru, Ueda Norihiro Mezon Gakuen, Miyazawa Shuhei, Tagami Katsuya, Nomoto Seiichiro, Okita Makoto, Shimomura Naoyuki, Kaneko Toshihiko Sejuru Kasuga, Fujimoto Masatoshi, Murakami Manabu, Oketani Kiyoshi, Fujisaki Hideaki, Shibata Hisashi, Wakabayashi Tsuneo: Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same.. Eisai, June 1, 1988: EP0268956-A2 (49 worldwide citation)

The invention provides pyridine derivatives represented by general formula: wherein R and R may be the same or different from each other and each stand for a hydrogen atom, a lower alkyl, lower alkoxy, halogenated lower alkyl, lower alkoxycarbonyl or carboxyl group or a halogen atom; X stands for a ...


3
Okano Kazuo, Miyazawa Shuhei, Clark Richard Stephen John, Abe Shinya, Kawahara Tetsuya, Shimomura Naoyuki, Asano Osamu, Yoshimura Hiroyuki, Miyamoto Mitsuaki, Sakuma Yoshinori, Muramoto Kenzo, Obaishi Hiroshi, Harada Koukichi, Tsunoda Hajime, Katayama Satoshi, Yamada Kouji, Souda Shigeru, Machida Yoshimasa, Katayama Kouichi: 1,4-diazepine derivative and its pharmaceutical use.. Eisai, May 9, 1990: EP0367110-A1 (31 worldwide citation)

A triazolo-1,4-di-azepine compound of the below given formula and a pharmacologically acceptable salt thereof are disclosed and useful in the pharmaceutical field, especially to allergic diseases. in which R1 and R2 are hydrogen or an alkyl, R3 is hydrogen or a halogen, R4 is hydrogen or an alkyl, X ...


4
Watanabe Nobuhisa, Kabasawa Yasuhiro, Takase Yasutaka, Ozaki Fumihiro, Ishibashi Keiji, Miyazaki Kazuki, Matsukura Masayuki, Souda Shigeru, Miyake Kazutoshi, Ishihara Hiroki, Kodama Kohtaro, Adachi Hideyuki: Fused pyridazine compound. Eisai, July 24, 1996: EP0722936-A1 (29 worldwide citation)

A fused pyridazine compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof which exhibits an inhibitory activity against cyclic GMP phosphodiesterase (hereinafter referred to as "cGMP-PDE"). The compounds are useful as preventive and therapeutic agent ...


5
Sato Masaru, Souda Shigeru: Benzimidazole derivatives as antimicrobal agent against campylobacter pylon.. Eisai, March 9, 1994: EP0585722-A1 (22 worldwide citation)

The compounds having the following formula (I) wherein n is 0 or 1; or the pharmaceutically acceptable salts thereof may be used for the preparation of a medicament for preventing, improving and treating a disease caused by the bacterium Campylobacter pylori, in particular peptic ulcer or gastritis ...


6
Takase Yasutaka, Watanabe Nobuhisa, Adachi Hideyuki, Kodama Kohtaro, Ishihara Hiroki, Saeki Takao, Souda Shigeru: Quinazoline compound.. Eisai, August 30, 1995: EP0669324-A1 (13 worldwide citation)

A quinazoline compound represented by general formula (I), which is useful as a medicine having the activity as a calmodulin-dependent cGMP-PDE inhibitor, or a pharmacologically acceptable salt thereof wherein R, R, R, R and R represent each independently hydrogen, lower alkyl, etc.; and R ad R repr ...


7
Ozaki Fumihiro, Ishibashi Keiji Parkhill Tsuku, Ikuta Hironori, Ishihara Hiroki, Souda Shigeru: Anthranilic acid derivative. Eisai, December 13, 1995: EP0686625-A1 (12 worldwide citation)

An anthranilic acid derivative having a cGMP-PDE inhibitory activity and represented by general formula (I), or a pharmacologically acceptable salt thereof wherein R, R, R and R represent each independently hydrogen, halogen, hydroxy, optionally halogenated lower alkyl, optionally halogenated lower ...


8
Souda Shigeru, Ueda Norihiro, Miyazawa Shuhei, Tagami Katsuya, Nomoto Seiichiro, Okita Makoto, Shimomura Naoyuki, Kaneko Toshihiko, Fujimoto Masatoshi, Murakami Manabu, Oketani Kiyoshi, Fujisaki Hideaki, Shibata Hisashi, Wakabayashi Tsuneo: Pyridine derivative and therapeutic agent for ulcer comprising the same.. Eisai, December 21, 1988: EP0295603-A1 (9 worldwide citation)

A pyridine compound having the formula is disclosed and useful to treat the peptic ulcer. wherein R and R which may be the same or different are each a hydrogen atom, a lower alkyl group, a lower alkoxy group, a halogenated lower alkyl group, or a halogen atom, R and R which may be the same or diffe ...


9
Souda Shigeru, Ueda Norihiro, Miyazawa Shuhei, Tagami Katsuya, Nomoto Seiichiro, Okita Makoto, Shimomura Naoyuki, Kaneko Toshihiko, Fujimoto Masatoshi, Murakami Manabu, Oketani Kiyoshi, Fujisaki Hideaki, Shibata Hisashi, Wakabayashi Tsuneo: Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and process for preparing the same.. Eisai, May 24, 1995: EP0654471-A1 (8 worldwide citation)

The invention provides pyridine derivatives represented by general formula: wherein R and R may be the same or different from each other and each stand for a hydrogen atom, a C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkyl, (C1-6 alkoxy)carbonyl or carboxyl group or a halogen atom; X stands for a gr ...


10
Tagami Katsuya, Yoshida Ichiro, Kobayashi Naoki, Fukuda Yoshio, Eguchi Yoshihito, Nakagawa Makoto, Hiyoshi Hironobu, Ikuta Hironori, Kaino Makoto, Hayashi Kenji, Ohtsuka Issei, Abe Shinya, Souda Shigeru: Phosphorus-substituted isoprenoid derivative.. Eisai, August 10, 1994: EP0609440-A1 (7 worldwide citation)

A phosphorus-substituted isoprenoid derivative represented by general formula (I) or a pharmacologically acceptable salt thereof, useful for preventing and treating diseases for which a squalene synthetase inhibition is efficacious. In formula (I), R and R represent each hydrogen, lower alkyl, cyclo ...